CMV high‐risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept-Reference-Cited by-同舟云学术

CMV high‐risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept

Published:2020-08-08 Issue:1 Volume:21 Page:208-221
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am. J. Transplant.

Author:

Karadkhele Geeta¹,Hogan Julien¹^ORCID,Magua Wairimu¹,Zhang Weiwen¹,Badell Idelberto Raul¹,Mehta Aneesh²,Lyon Marshall²,Pastan Stephen¹^ORCID,Pearson Thomas C.¹,Larsen Christian P.¹^ORCID

Affiliation:

1. Department of Surgery Emory Transplant CenterEmory School of Medicine Atlanta Georgia USA

2. Infectious Diseases Department Department of Medicine Emory School of Medicine Atlanta Georgia USA

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.16132

Reference24 articles.

1. Lack of Improvement in Renal Allograft Survival Despite a Marked Decrease in Acute Rejection Rates Over the Most Recent Era

2. OPTN/SRTR 2017 Annual Data Report: Kidney

3. Belatacept and Long-Term Outcomes in Kidney Transplantation

4. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT

5. A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of resistant and refractory cytomegalovirus infections after transplantation;Expert Review of Anti-infective Therapy;2024-09-05

2. Belatacept based immunosuppression: What and when to combine?;Transplant Immunology;2024-08

3. Evolving trends in immunosuppression use and cytomegalovirus infection risk over the past decade in kidney transplantation;Transplant Infectious Disease;2024-06-30

4. Zusammenfassung der 2. internationalen Konsensusleitlinie zum Management von BK-Polyomavirus bei Patienten nach Nierentransplantation;Die Nephrologie;2024-06-26

5. The Conversion From Mycophenolic Acid to Mammalian Target of Rapamycin Inhibitor Reduces the Incidence of Cytomegalovirus Replication in Belatacept-Treated Kidney-Transplant Recipients;Kidney International Reports;2024-06